From Name:
From Email:
To Name:
To Email:

Optional Message:

EBBINGHAUS: Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function

from TCTMD

Reducing LDL cholesterol to "unprecedented" low levels with a PCSK9 inhibitor — down to less than 25 milligram/deciliter in some patients — does not adversely affect cognitive function, according to the results of the EBBINGHAUS study. In a subgroup of patients who underwent cognitive testing in FOURIER, the large cardiovascular morbidity and mortality trial testing evolocumab (Repatha, Amgen), investigators report no differences between evolocumab- and placebo-treated patients in terms of performance on a battery of neuropsychological tests. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063